DaVita HealthCare Partners Inc. (NYSE:DVA) saw strong trading volume on Monday . 1,885,216 shares were traded during trading, a decline of 0% from the previous session’s volume of 1,891,457 shares.The stock last traded at $65.25 and had previously closed at $64.48.

Several research analysts have recently commented on the company. Wells Fargo & Co. reissued a “buy” rating on shares of DaVita HealthCare Partners in a report on Saturday, June 4th. Robert W. Baird reissued a “buy” rating on shares of DaVita HealthCare Partners in a report on Sunday, May 8th. Zacks Investment Research raised DaVita HealthCare Partners from a “hold” rating to a “buy” rating and set a $87.00 price objective for the company in a report on Tuesday, July 5th. TheStreet raised DaVita HealthCare Partners from a “hold” rating to a “buy” rating in a report on Wednesday, May 4th. Finally, JPMorgan Chase & Co. boosted their price objective on DaVita HealthCare Partners from $74.00 to $75.00 and gave the stock a “neutral” rating in a report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $78.00.

The company’s 50-day moving average price is $74.65 and its 200 day moving average price is $73.28. The firm has a market capitalization of $13.48 billion and a P/E ratio of 37.91.

DaVita HealthCare Partners (NYSE:DVA) last issued its earnings results on Monday, August 8th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.03. The business had revenue of $3.72 billion for the quarter, compared to the consensus estimate of $3.67 billion. The firm’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period last year, the business posted $0.95 EPS. Analysts expect that DaVita HealthCare Partners Inc. will post $3.78 EPS for the current year.

In related news, Director Pamela M. Arway sold 10,824 shares of DaVita HealthCare Partners stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $77.16, for a total transaction of $835,179.84. Following the sale, the director now owns 36,394 shares of the company’s stock, valued at approximately $2,808,161.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jeanine Marie Jiganti sold 4,620 shares of DaVita HealthCare Partners stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $77.45, for a total value of $357,819.00. Following the sale, the insider now directly owns 7,590 shares in the company, valued at approximately $587,845.50. The disclosure for this sale can be found here.

A number of institutional investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC boosted its position in DaVita HealthCare Partners by 0.5% in the fourth quarter. Jennison Associates LLC now owns 440,195 shares of the company’s stock valued at $30,686,000 after buying an additional 2,084 shares in the last quarter. KBC Group NV boosted its position in DaVita HealthCare Partners by 82.7% in the fourth quarter. KBC Group NV now owns 35,965 shares of the company’s stock valued at $2,507,000 after buying an additional 16,281 shares in the last quarter. Utah Retirement Systems boosted its position in DaVita HealthCare Partners by 0.3% in the fourth quarter. Utah Retirement Systems now owns 31,618 shares of the company’s stock valued at $2,204,000 after buying an additional 100 shares in the last quarter. BlackRock Advisors LLC boosted its position in DaVita HealthCare Partners by 34.8% in the fourth quarter. BlackRock Advisors LLC now owns 754,037 shares of the company’s stock valued at $52,564,000 after buying an additional 194,863 shares in the last quarter. Finally, Bridgewater Associates LP purchased a new position in DaVita HealthCare Partners during the fourth quarter valued at $2,227,000.

DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.